Somu Subramaniam - Icad Independent Director

ICAD Stock  USD 1.61  0.01  0.63%   

Director

Mr. Somu Subramaniam is an Independent Director of iCAD Inc. He is the cofounder and Managing Partner of New Science Ventures . He serves on the Board of Directors of Achronix Semiconductor Corporationrationration, Akarna Therapeutics, Alexar Therapeutics, Ario Pharmaceuticals, Cambridge Epigenetix, Dali Wireless, Dezima Pharma, Juventas Therapeutics, Oxyrane, Resolve Therapeutics, Svelte Medical Systems, TigerText, Vaultive, Vascular Therapeutics and iCAD. Mr. Subramaniam has also served on the Boards of Ception, BioVex, Lightwire . Prior to founding NSV, Mr. Subramaniam was a director at McKinsey Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries since 2010.
Age 59
Tenure 14 years
Professional MarksMBA
Address 98 Spit Brook Road, Nashua, NH, United States, 03062
Phone603 882 5200
Webhttps://www.icadmed.com
Subramaniam holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.

Icad Management Efficiency

The company has return on total asset (ROA) of (0.1032) % which means that it has lost $0.1032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2052) %, meaning that it created substantial loss on money invested by shareholders. Icad's management efficiency ratios could be used to measure how well Icad manages its routine affairs as well as how well it operates its assets and liabilities. As of March 29, 2024, Return On Capital Employed is expected to decline to -0.23. In addition to that, Return On Assets is expected to decline to -0.12. At present, Icad's Fixed Asset Turnover is projected to slightly decrease based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.76, whereas Non Currrent Assets Other are forecasted to decline to about 416.7 K.
The company currently holds 461 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Icad Inc has a current ratio of 3.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Icad until it has trouble settling it off, either with new capital or with free cash flow. So, Icad's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Icad Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Icad to invest in growth at high rates of return. When we think about Icad's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Gary JacobsMotus GI Holdings
59
Oded YatzkanMedigus Ltd ADR
49
Erez HaimovitzMedigus Ltd ADR
N/A
Ori HershkovitzMedigus Ltd ADR
39
Darren ShermanMotus GI Holdings
45
Yuval YanaiMedigus Ltd ADR
65
Yair RabinowitchMedigus Ltd ADR
71
Shervin KorangyMotus GI Holdings
43
Yair RabinovitchMedigus Ltd ADR
67
Samuel NussbaumMotus GI Holdings
69
Eitan MachoverMedigus Ltd ADR
55
Jeremy StarkweatherMedigus Ltd ADR
42
Doron BirgerMedigus Ltd ADR
66
Gary PrudenMotus GI Holdings
56
Efrat VenkertMedigus Ltd ADR
46
Anat NaschitzMedigus Ltd ADR
N/A
Aviel ShapiraMedigus Ltd ADR
61
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire. Icad operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 136 people. Icad Inc (ICAD) is traded on NASDAQ Exchange in USA. It is located in 98 Spit Brook Road, Nashua, NH, United States, 03062 and employs 29 people. Icad is listed under Health Care Technology category by Fama And French industry classification.

Management Performance

Icad Inc Leadership Team

Elected by the shareholders, the Icad's board of directors comprises two types of representatives: Icad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icad. The board's role is to monitor Icad's management team and ensure that shareholders' interests are well served. Icad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icad's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Sassine, Director
Stephen Sarno, Interim Officer
Michelle Strong, Chief Officer
Jonathan Go, Sr. VP of RandD
Zack Kubow, IR Contact Officer
Scott Areglado, Vice President Controller
Brian Testa, Chief Officer
Susan Wood, Director
Richard Christopher, CFO, Executive Vice President
Vasu Avadhanula, Chief Officer
Lawrence Howard, Chairman of the Board
Anthony Takazawa, Director Relations
Robert Goodman, Director
Elliot Sussman, Independent Director
Dana Brown, CEO President
Kevin Burns, President, CFO, COO, Treasurer and Secretary
Somu Subramaniam, Independent Director
Rakesh Patel, Director
Eric Lonnqvist, Chief Officer
Steven Rappaport, Independent Director
Annette Heroux, Vice Administration
Michael Klein, Ex Director
Stacey Stevens, Sr. VP of Marketing and Strategy
Anthony Ecock, Independent Director
Rachel Brem, Independent Director
Jeffrey Sirek, Chief Officer
Kenneth Ferry, CEO and Director
Bill Keyes, Senior Operations
Peter Graham, Senior Sales

Icad Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Icad Inc is a strong investment it is important to analyze Icad's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Icad's future performance. For an informed investment choice regarding Icad Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Icad Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Icad Inc information on this page should be used as a complementary analysis to other Icad's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Icad Stock analysis

When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Bonds Directory
Find actively traded corporate debentures issued by US companies
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Is Icad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.49)
Revenue Per Share
0.676
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.10)
Return On Equity
(0.21)
The market value of Icad Inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.